1. Cytosolic 5'-Nucleotidase II Silencing in Lung Tumor Cells Regulates Metabolism through Activation of the p53/AMPK Signaling Pathway
- Author
-
Mercedes Garcia-Gil, Marcella Camici, Rossana Pesi, Lars Petter Jordheim, Maria Grazia Tozzi, Roberta Moschini, Simone Allegrini, and Lucia Piazza
- Subjects
Enzymologic ,p53 ,AMPK ,Lung Neoplasms ,AMP-Activated Protein Kinases ,5'-nucleotidase ,AMP-activated protein kinase ,Energy charge ,Biology (General) ,5'-Nucleotidase ,Spectroscopy ,Tumor ,biology ,Mucoepidermoid ,Chemistry ,General Medicine ,Computer Science Applications ,Cell biology ,Gene Expression Regulation, Neoplastic ,Signal transduction ,Signal Transduction ,QH301-705.5 ,Allosteric regulation ,CN-II ,Lactate ,Metabolic regulation ,P53 ,Carcinoma, Mucoepidermoid ,Cell Line, Tumor ,Energy Metabolism ,Gene Expression Regulation, Enzymologic ,Gene Silencing ,Humans ,Tumor Suppressor Protein p53 ,Adenylate kinase ,Catalysis ,Article ,Cell Line ,Inorganic Chemistry ,Physical and Theoretical Chemistry ,Protein kinase A ,Molecular Biology ,QD1-999 ,Neoplastic ,lactate ,Organic Chemistry ,Carcinoma ,Gene Expression Regulation ,biology.protein ,metabolic regulation ,cN-II - Abstract
Cytosolic 5′-nucleotidase II (cN-II) is an allosteric catabolic enzyme that hydrolyzes IMP, GMP, and AMP. The enzyme can assume at least two different structures, being the more active conformation stabilized by ATP and the less active by inorganic phosphate. Therefore, the variation in ATP concentration can control both structure and activity of cN-II. In this paper, using a capillary electrophoresis technique, we demonstrated that a partial silencing of cN-II in a pulmonary carcinoma cell line (NCI-H292) is accompanied by a decrease in adenylate pool, without affecting the energy charge. We also found that cN-II silencing decreased proliferation and increased oxidative metabolism, as indicated by the decreased production of lactate. These effects, as demonstrated by Western blotting, appear to be mediated by both p53 and AMP-activated protein kinase, as most of them are prevented by pifithrin-α, a known p53 inhibitor. These results are in line with our previous observations of a shift towards a more oxidative and less proliferative phenotype of tumoral cells with a low expression of cN-II, thus supporting the search for specific inhibitors of this enzyme as a therapeutic tool for the treatment of tumors.
- Published
- 2021